
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines Ltd shows a promising financial outlook, primarily due to the strong preference for its leading product Brukinsa among oncologists, which is projected to significantly contribute to peak sales of approximately $7.1 billion. The company's innovative asset, sonrotoclax, emerges as the most advanced BCL2 inhibitor, with expectations of surpassing the performance of competitors, bolstering potential revenue streams, including estimated peak sales of $3.4 billion. Furthermore, BeOne Medicines anticipates robust growth, exceeding 40% year-over-year into 2025, with plans for profitable operations and positive free cash flow expected to materialize by that same year.
Bears say
BeOne Medicines Ltd faces a negative outlook primarily due to several fundamental challenges that could significantly impact its financial performance. The potential for slower-than-expected uptake of its products, combined with the risk of unsuccessful pipeline programs and adverse regulatory outcomes, could lead to diminished commercial viability and a substantial decrease in stock value. Additionally, being positioned within a crowded oncology market coupled with high cash burn on its research pipeline raises concerns about the company’s ability to develop marketable drugs, further diminishing investor confidence.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares